Suchergebnisse - "Meiser, Karin"

PubPharm (19)

1

DFV890 : a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

enthalten in: Infection | 2023

von Madurka, I. | Vishnevsky, A. | Soriano, J. | +116

2

ANTI-INTERLEUKIN 1 BETA ANTIBODIES FOR TREATMENT OF SICKLE CELL DISEASE

enthalten in: Europäisches Patentamt | 2023

von GUICHARD ALEXANDRE YANN | KOVARIK JIRI | LI YUE | +4

3

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

enthalten in: Infection | 2022

von Madurka, I. | Vishnevsky, A. | Soriano, J. | +15

4

A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia

enthalten in: Blood | 2022

von Rees, D. | Kilinc, Y. | Unal, S. | +18

CommentIn: Blood. 2022 Apr 28;139(17):2578-2580. - PMID 35482344

5

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression : primary results from the randomised, double-blind, phase III FUTURE 5 study

enthalten in: Annals of the rheumatic diseases | 2018

von Mease, P. | van der Heijde, D. | Landewé, R. | +10

CommentIn: Ann Rheum Dis. 2019 Sep;78(9):e97. - PMID 29853450

6

Comparing QT interval variability of semiautomated and high-precision ECG methodologies in seven thorough QT studies-implications for the power of studies intended for definitive evaluation of a drug's QT effect

enthalten in: Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc | 2017

von Meiser, K. | Jordaan, P. | Latypova, S. | +1

7

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses

enthalten in: The Journal of allergy and clinical immunology | 2016

von Gauvreau, G. | Arm, J. | Boulet, L. | +22

8

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses

enthalten in: The journal of allergy and clinical immunology | 2016

von Gauvreau, G. | Arm, J. | Boulet, L. | +22

9

Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment : An open-label, single-dose, parallel-group study

enthalten in: International journal of clinical pharmacology and therapeutics | 2015

von David, O. | Pryce, M. | Meiser, K. | +5

10

Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study

enthalten in: International journal of clinical pharmacology and therapeutics | 2015

von David, O. | Pryce, M. | Meiser, K. | +5